- Page 1 and 2:
Head and Neck II: Oropharynx, Laryn
- Page 4 and 5:
OROPHARYNX-Sites Base of tongue Sof
- Page 6 and 7:
INCIDENCE OF LYMPH NODE METASTASES
- Page 8 and 9:
CA. OF THE OROPHARYNX INCIDENCE OF
- Page 10 and 11:
Oropharyngeal CA: Treatment Volume
- Page 12 and 13:
RTOG 73-03 Oral Cavity And Orophary
- Page 14 and 15:
Surgery and Adjuvant RT vs. CCRT in
- Page 16 and 17:
Stage III/IV Head and Neck CA: Rand
- Page 18 and 19:
CA. OF THE TONSILLAR REGION LOCAL C
- Page 20 and 21:
CARCINOMA OF THE TONSIL LOCAL CONTR
- Page 22 and 23:
BASE OF TONGUE IMPLANTS Patient Sel
- Page 24 and 25:
BASE OF TONGUE IMPLANTS Dose to the
- Page 26 and 27:
Trans-Tasman Radiation Oncology PPo
- Page 28 and 29:
RTOG 90-03 PHASE III STUDY OF ALTER
- Page 32 and 33:
CB: 33% Late Grade 3-4 Toxicity
- Page 34 and 35:
• N=77 • IV=83% RTOG 99-14 Ang
- Page 36 and 37:
Gortec French Study DDenis i et t a
- Page 38 and 39:
French Trial: Oropharyngeal CA (D (
- Page 40 and 41:
There is also site-specific orophar
- Page 42 and 43:
Why shouldn’t we just treat all a
- Page 44 and 45:
Chemoradiotherapy: Late FT Dependen
- Page 46 and 47:
Chemoradiotherapy: Late FT Dependen
- Page 48 and 49:
An example of patient with late eff
- Page 50 and 51:
Historical RT Dose Escalation • I
- Page 52 and 53:
IMRT in the Treatment of Oropharyng
- Page 54 and 55:
Patients Population From 9/1998 to
- Page 56 and 57:
Local Control 3-year 94.4% 5-year 9
- Page 58 and 59:
Local Failure versus T-stage • T1
- Page 60 and 61:
Toxicities : Acute • Mucositis gr
- Page 62 and 63: IMRT for oropharynx: available data
- Page 64: Mean Doses Right Parotid 19.80 Gy R
- Page 70 and 71: % >G2 LENT SOM Subjective Xerostomi
- Page 72 and 73: Conclusions • RT preferred f d ov
- Page 74 and 75: Conclusions • Careful selection o
- Page 76 and 77: T1 T1-2NO 2NO Gl Glottic tti Cancer
- Page 78 and 79: T1 Carcinoma of the Glottis Local C
- Page 80 and 81: LOCAL CONTROL OF T1 LESIONS Locall
- Page 82 and 83: T2 Carcinoma of the Glottis Local o
- Page 84 and 85: LOCAL CONTROL OF T2 LESIONS Control
- Page 86 and 87: LOCAL CONTROL FOR T2 LESIONS Local
- Page 88 and 89: Randomized trial on RT fraction siz
- Page 90 and 91: Meta-analysis of Impaired VC Mobili
- Page 92 and 93: RTOG 91-11 Phase III Trial to Prese
- Page 94 and 95: T4 T4a: Thyroid Th id Cartilage C i
- Page 96 and 97: Induction Chemotherapy Followed By
- Page 98 and 99: Stage T3 Carcinoma of the Glottis R
- Page 100 and 101: Carcinoma of the Supraglottis % LLo
- Page 102 and 103: VA LARYNGEAL CA. STUDY Surgery Radi
- Page 104 and 105: VA LARYNX PRESERVATON STUDY Surgery
- Page 106 and 107: R A N D O M GETTEC Trial - T3 Laryn
- Page 108 and 109: Does Vocal Cord Fixation Preclude N
- Page 110 and 111: RTOG 91-11 Ph Phase III TTrial i l
- Page 114 and 115: Squamous Cell Head and Neck Cancer
- Page 116 and 117: Functional Organ Preservation with
- Page 118 and 119: Wh What t is i th the bbest t RT FF
- Page 120 and 121: Stage III or IV of f sq cell ll ca
- Page 122 and 123: HHypopharynx h
- Page 124 and 125: EORTC 24891 LARYNX PRESERVATION FOR
- Page 126: CConcurrent Ch Chemoradiotherapy di